Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 360

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1A
Chunk 360
---
 less than 1% of net product sales for each of the respective periods.

108

Table of ContentsSupernus Pharmaceuticals, Inc.Notes to Consolidated Financial Statements (Continued)

The following table shows the percentage of net product sales to total net product sales:Percentage of Net Product SalesYear Ended December 31,202420232022Qelbree38%24%9%GOCOVRI20%21%16%Oxtellar XR16%20%18%APOKYN12%13%12%Trokendi XR10%16%40%Other(1)4%6%5%Total100%100%100%______________________________(1)   Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.

4. Investments

Marketable SecuritiesUnrestricted available-for-sale marketable securities held by the Company are as follows (dollars in thousands):December 31, 2024December 31, 2023Corporate, U.S. government agency and municipal debt securitiesAmortized cost$384,481 $197,153 Gross unrealized gains89 5 Gross unrealized losses(289)(721)Total fair value$384,281 $196,437  As of December 31, 2024, all of our unrestricted available-for-sale marketable securities have contractual maturities of one year or less.There was no impairment on any available-for-sale marketable securities as of December 31, 2024 and December 31, 2023.Investment in NavitorIn April 2020, the Company entered into a development agreement (the Development Agreement) with Navitor Pharmaceuticals, Inc. (Navitor Inc.). The Company can terminate the Development Agreement upon 30 days' notice. Under the terms of the Development Agreement, the Company and Navitor Inc. will jointly conduct a Phase 2 clinical program for NV-5138 (SPN-820) for treatment-resistant depression. The Company will bear all of the Phase 1 and Phase 2 development costs incurred by either party, up to a maximum of $50 million, which amount could be increased under the terms of the Development Agreement upon Navitor Inc.’s request and the Company’s consent. In 2020, the Company paid a one-time, nonrefundable, and non-creditable fee of $10 million for the option to acquire or license NV-5138 (SPN-820) and made a $